top of page


What is the CardioTech Accelerator? 

The CardioTech Accelerator is a pilot-driven & business-oriented international program. It aims to develop industrial projects between forward-thinking startups/scaleups and leading corporations by matching both the corporate and startup business objectives. 


How long is the program? 

The program is 15 weeks long. Corporates and startups may decide to continue the pilot after the end of the program to negotiate further possibilities for interaction such as commercial agreements, co-development agreements, investments or acquisitions. 


Do I have to give equity or pay any money to the program? 

No, there is no equity or need for payment to the program to participate. The corporate partners may want to invest and agree to the terms prior to the program. 


Why should I apply? 

If you want to work on actual industrial pilots, test your solution’s readiness level by working with an industrial or clinical partner, get your clinical trial started, build your regulatory strategy, gain more traction or enter a new market, this is the right program for you. The CardioTech Accelerator is a radical opportunity to push your venture forward with the help of committed corporates that are ready to share their capabilities to drive innovation and experienced mentors to facilitate each project. 


Do I need to relocate to Milan? 

No, there is no need to relocate for the entire program. We try to be as founder friendly as possible though we do require (in compliance with all Covid-19 regulations) participation for our launch, demo day and depending on your pilot, for one or more members of your team to attend any meetings/labs/activities in order to ensure the project’s success. 


Will you pay my travel expenses? 

No, we do not reimburse or pay for any travel expenses. 


What does it take to enter the CardioTech Accelerator? 

This is not a traditional accelerator. Being a corporate scale-up program it’s not about how good your solution is but more about how good of a fit it is with our Corporate Partners’ innovation needs. Please refer to the “Who Should Apply” section for more information. 

We do look for a great, flexible and collaborative team that is motivated and ready to work with an industrial or clinical partner. 

I can’t find the right technology trend for my startup, does that mean I should not apply? 

Not necessarily, if your company is developing breakthrough innovative solutions to make patients’ lives better, safeguard people’s health or make healthcare systems more efficient, you should definitely apply and select the macro-trend that you feel is closes to what you do. 


What kind of companies do you accelerate?


We describe ourselves as a “later stage accelerator or scale-up program”. This means that if you are just completing your pre-clinical work, or you are just waiting for regulatory approval or, again, you are already on the market and are looking to keep growing, you are definitely a great fit for this program. 

However, we are equally comfortable working with early stage companies that feel they could benefit from the collaboration with an industrial partner. 


I want to know more about the Accelerator’s Partners 

Deloitte: the Deloitte Life Sciences & Health Care Global Network can count on over 13.000 dedicated people spread across 90+ Countries. Our clients include 8 of the 9 largest Health Care companies and 17 of the 18 largest Life Sciences companies. 

Daiichi Sankyo Italia: subsidiary of Daiichi Sankyo Europe GmbH, founded in 2006 by the merger of the Japanese companies Daiichi and Sankyo in Europe, is a global pharmaceutical group with over 100 years of scientific research behind it and a presence in over 20 countries around the world.

Serenità: The Reteserenità network has been operating for 25 years in assisting the elderly, sick and disabled, through a group of leading companies in their sectors, franchisee in over 60 Italian cities and over 2,500 customers every year.


I have more questions


If you have more questions please contact us at

bottom of page